Inion Appoints David Follows as Chief Commercial Officer

          New CCO to have a key role in Inion’s new commercial structure

Tampere, Finland and Takeley, UK. 1 June 2007… Inion Oy (LSE: IIN.L) (“Inion”), a company focused on the development of novel biodegradable medical implants has appointed David Follows as its new Chief Commercial Officer, effective 2 July 2007.

David (47) brings more than 27 years’ commercial experience to Inion, the past 20 years of which were spent in the medical devices industry with ETHICON and ETHICON Endo-Surgery, major subsidiaries of Johnson & Johnson. During his career David held positions of increasing responsibility within sales and marketing operations, and most recently was Managing Director of ETHICON Endo-Surgery UK, where he has devised and implemented commercial strategies that have led to a doubling of sales to £70 million over the past five years.

At Inion, David will have a key role as part of Inion’s new commercial structure. Specifically, he will have responsibility for building its commercial operations outside North America, including appointing distributors for Inion products in key markets, as well as bringing significant commercial and business discipline to the senior management team. He will report to Inion’s CEO Chris Lee and will be supported by sales and marketing teams headed by Carolyn Harvey (Sales Director) and Andreas Posel (Marketing Director).

Chris Lee, Inion’s Chief Executive Officer, commented: “David is a highly customer-focused and results-oriented individual, who has been very successful at developing and implementing commercial strategies. He has outstanding skills in the area of organising, leading and motivating teams. I am very pleased that someone of his experience and calibre is joining Inion and am very confident he will make a significant contribution to the success of Inion across every aspect of our business.”

David Follows, said: “Inion is at an exciting stage of development and I believe my experience is very well suited to building the commercial structures and processes necessary to growing Inion’s business in key markets. Inion’s technology and products have a real place in the spine and orthopaedic trauma segments it is focusing on and I am impressed with the ambitions and commitment of the company towards driving the strategy necessary to getting them established. I am looking forward to playing my part in this process.”

                                                          - ends -

For further information, please contact:

 Inion Oy      

Chris Lee, Chief Executive Officer
Julien Cotta, Chief Financial Officer 
Tel: +44 (0)1279 874 222

Citigate Dewe Rogerson

Mark Swallow / Helena Galilee / David Dible
Tel: +44 (0)207 638 9571

About Inion (www.inion.com)

Inion Oy is a medical devices company focused on the development and successful commercialisation of innovative biodegradable and bioactive implants in key target markets. The Company's target segments are Spine and Specialty Orthopaedics.

Inion’s core expertise and technology lies in the design and manufacture of innovative biodegradable plates, screws, pins and membranes, which are used to enhance the healing of bone or soft tissue injuries to the skeleton, such as those caused by trauma or by reconstructive surgery. Inion implants are made from its proprietary Inion Optima[TM] family of biomaterials, with properties tailored for specific surgical applications, in terms of strength, flexibility and rate of degradation.

Inion is also focused on developing proprietary new bioactive and biodegradable biomaterials that promote bone healing and accelerate patient rehabilitation.

Inion was incorporated in early 2000 and listed on the Official List of the UK Listing Authority in December 2004. The Company has an office and an R&D facility in the UK and head office, R&D and production facilities in Tampere, Finland.

This announcement includes "forward-looking statements" which include all statements other than statements of historical facts, including, without limitation, those regarding the Group's financial position, business strategy, plans and objectives of management for future operations (including development plans and objectives relating to the Group's products), and any statements preceded by, followed by or that include forward-looking terminology such as the words "targets", "believes", "estimates", "expects", "aims", "intends", "will", "can", "may", "anticipates", "would", "should", "could" or similar expressions or the negative thereof. Such forward-looking statements involve known and unknown risks, uncertainties and other important factors beyond the Group's control that could cause the actual results, performance or achievements of the Group to be materially different from future results, performance or achievements expressed or implied by such forward-looking statements. Such forward-looking statements are based on numerous assumptions regarding the Group's present and future business strategies and the environment in which the Group will operate in the future. Among the important factors that could cause the Group's actual results, performance or achievements to differ materially from those in forward-looking statements include those relating to Inion’s funding requirements, regulatory approvals, reliance on third parties, intellectual property, key personnel and other factors. These forward-looking statements speak only as at the date of this announcement. The Group expressly disclaims any obligation or undertaking to disseminate any updates or revisions to any forward-looking statements contained in this announcement to reflect any change in the Group's expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based. As a result of these factors, prospective investors are cautioned not to rely on any forward-looking statement.